Lv61
2710 积分 2022-01-11 加入
Discovery of the First Clinical Protein Degrader for the Treatment of Autoimmune Indications: Orally Bioavailable and Selective IRAK4 Degrader KT-474
1个月前
已完结
The potential of targeting CYP11B
1个月前
已完结
Baxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension
1个月前
已完结
Cancer therapy with antibodies
1个月前
已完结
Therapeutic Small Interfering RNA Targeting Complement C3 in a Mouse Model of C3 Glomerulopathy
1个月前
已完结
Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases
3个月前
已完结
Discovery of LC-MI-3: A Potent and Orally Bioavailable Degrader of Interleukin-1 Receptor-Associated Kinase 4 for the Treatment of Inflammatory Diseases
3个月前
已完结
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
3个月前
已完结
皖公网安备34019202002308
